Barron will step down from GSK effective August 2022 to join Altos Labs as CEO.

Hal joined GSK as Chief Scientific Officer and President, R&D on 1 January 2018. He was also appointed to the GSK Board of Directors as an Executive Director and member of the Science Committee.

Hal is responsible for all research and development of our pipeline molecules as well as life-cycle management of the approved medicines. He is a member of the Corporate Executive Team.

Prior to joining GSK in 2018,  Hal was President, R&D at Calico (California Life Company). Prior to this, he was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer.